Vinva Investment Management Boosts Stake in AbbVie Inc.

Investment firm increases holding in pharmaceutical company by 24%

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Vinva Investment Management Ltd. raised its stake in shares of AbbVie Inc. (NYSE:ABBV) by 24.0% during the third quarter, according to a recent SEC filing. The institutional investor now owns 162,584 shares of the pharmaceutical company's stock, worth $36.28 million.

Why it matters

AbbVie is a major pharmaceutical company with a diverse portfolio of drugs across several therapeutic areas. Institutional investors closely watch changes in ownership stakes, as they can signal confidence or concerns about a company's future prospects.

The details

Vinva Investment Management increased its position in AbbVie by purchasing an additional 31,451 shares during the third quarter. The firm now holds a 0.7% stake in AbbVie, making it the company's 16th largest institutional shareholder. AbbVie's stock price has fluctuated between $164.39 and $244.81 over the past 52 weeks.

  • Vinva Investment Management increased its AbbVie stake during the third quarter of 2025.
  • AbbVie is scheduled to pay a quarterly dividend of $1.73 per share on May 15, 2026 to shareholders of record as of April 15, 2026.

The players

Vinva Investment Management Ltd

An institutional investment firm that manages a portfolio of stocks, including a 0.7% stake in pharmaceutical company AbbVie Inc.

AbbVie Inc.

A global biopharmaceutical company that focuses on discovering, developing and commercializing specialty medicines across multiple therapeutic areas, including immunology, oncology, neuroscience and women's health.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to closely monitor changes in institutional ownership of major pharmaceutical companies like AbbVie, as they can provide insights into market sentiment and future growth potential.”

— Lauren Steadman, Finance Reporter (transcriptdaily.com)

What’s next

Investors will be watching to see if other major institutional investors follow Vinva Investment Management's lead and increase their stakes in AbbVie ahead of the company's next quarterly dividend payment.

The takeaway

The increase in Vinva Investment Management's AbbVie holdings suggests continued confidence in the pharmaceutical company's long-term growth prospects, despite some recent stock price volatility.